Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

Item

http://www.wikidata.org/entity/Q35012462

Q35012462

about

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 Antibodies in HIV-1 vaccine development and therapy A global approach to HIV-1 vaccine development Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41 Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor New concepts in HIV-1 vaccine development Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein Immune-correlates analysis of an HIV-1 vaccine efficacy trial Survivors Remorse: antibody-mediated protection against HIV-1.Current views on the potential for development of a HIV vaccine.HIV prevention transformed: the new prevention research agenda Human immunodeficiency virus vaccine trials Closing the door to human immunodeficiency virus.Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41.4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Rational antibody-based HIV-1 vaccine design: current approaches and future directions International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Scaffolding to build a rational vaccine design strategy.Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1.

P2860

Q24635002-FD14E18B-0521-4AB6-B3EB-3876C000E278 Q26767258-D11D4944-0751-4190-9A86-B36E6983AAB9 Q26782237-F51F3D2C-0974-44FB-87FF-31719D123194 Q27011574-D8B9E342-F769-40A7-B2DA-D8375CBFA68D Q27024614-A2CD63F2-9D93-4FCC-B908-CB9F02B03954 Q27312171-CC236C7E-14B3-48B7-97EE-D6BFC9193839 Q27313556-F89A15FC-86EB-4802-9A2E-539517F086D2 Q27318508-838E3E02-6A1D-45E2-9B51-17D36F339338 Q27324184-8FD983A6-C8D1-43F3-93AE-CE8C83749930 Q27662155-4D03D056-84B2-444D-9FB1-FE7F30075075 Q27674878-BAC88327-8E4A-407A-A086-4DC50ABA0310 Q27675260-5C5EA212-3CEA-4468-8D38-62C7E4745232 Q27684529-71D7E07B-3D41-4D83-B47B-ACA91CFC056D Q28067027-1F1EDD5F-29DA-48A9-8782-3F185FCA5DF5 Q28068018-608A36D9-F29E-4124-8B8D-C4254664B151 Q28242631-BA8B0B5D-C804-4828-9D17-B0693069AC5C Q28484544-64C323C4-4F05-46F6-B4C9-5D6697576EE8 Q28535583-DD40A8E1-56F1-4866-B2BD-94BDB081F5EA Q28545185-F8D9ACA7-3619-4552-A0D1-FBB2CB21825D Q28732043-086C2540-B28A-44AE-8890-ACD5EDFEB457 Q29306052-B6C307D7-7756-4135-8BFC-D95FAD75D53B Q29617377-DC7CCCD9-87B4-4002-9BC1-F1DDCBE0FDEF Q30238730-A97E78EF-AC1B-490C-A133-25D8902DCFE2 Q30397595-2E111460-6149-49DA-AE9C-CFB34F578BDE Q30404963-A0992334-6CA3-4142-AEB4-C513765BB0E9 Q30424366-DC86CE11-6247-4C00-9328-E0C960B5D7F7 Q30428089-4BCA2AC2-F5D6-4AAC-8B50-3F82A3F2CB4B Q30601090-C4DA9EBC-0E00-4BB8-A40B-DF02045C8E20 Q33547451-43EB2565-95B7-4E9C-9DA4-079D4C1EF643 Q33611645-131585E7-455F-4012-A7C1-D244F9F95E3E Q33620546-0CB2E893-7847-4885-9892-F2FDCFBBBBB0 Q33887674-98DBD0B3-F3F5-4E1A-8EE2-F700DDB87B30 Q33937285-01E5E421-C8EF-4904-8FBC-7983714F21BB Q33963580-A569D05E-8F0F-476F-B128-B67C5B37AFE0 Q34023249-19F53423-B276-4BC5-BDC5-02BAAA81B247 Q34047445-C8D36F2F-61A6-4A09-A765-0BD6DD070617 Q34053295-D99797ED-7A1B-425C-8BB5-9D979EFC247D Q34230556-7EF6F3D3-1330-45A2-8961-47C1866B7BCB Q34241394-5BC1FC09-B189-4669-AE4A-8054FEF34E19 Q34242643-627D9788-565C-46E2-BD0A-A4318862932D

P2860

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

Item

http://www.wikidata.org/entity/Q35012462

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu